PTEN Gene clinical trials
24 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
- Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
- Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- Rash & Diarrhea Prophylaxis With Capivasertib
- Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
- A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
- Zanzalintinib in Men With Aggressive Variant Prostate Cancer
- Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
- Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
- Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
- Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
- Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
- Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “PTEN Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.